trial · primary record
Zilovertamab vedotin
Lymphoma, Large B-Cell, Diffuse
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 594 |
| Primary completion | 2032-12-16 |
| Primary endpoint | Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response Criteria |
| Registry ID | NCT06890884 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:54.908Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06890884
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Zilovertamab vedotin · compound